Emergex Vaccines Holding Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Emergex Vaccines Holding Ltd.
Moderna has just secured its third global authorization for its COVID-19 vaccination in Israel, while the European Medicines Agency's review has been delayed.
Coronavirus Notebook: EU Opinion On Moderna’s mRNA-1273 Expected This Week, UK Boosts Vaccine Rollout As Lockdown Imposed
UK biotech firm Emergex has signed a deal with Brazil’s Biocruz for the development of a T-cell based vaccine, and the Philippines regulator has issued a warning after reports that members of the country’s presidential guard received an unauthorized vaccine produced by China’s Sinopharm.
InflaRx and Relief Therapeutics/NeuroRx are investigating potential new treatments for COVID-19-induced pneumonia and for coronavirus-related ARDS.
Plus: Valneva confirms supply deal with the UK government for its inactivated vaccine candidate; Humanigen expands manufacturing ahead of Phase III data.
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Emergex Vaccines Holding Limited, ImmProNano Inc.